Gofen & Glossberg LLC IL Sells 3,901 Shares of Zoetis Inc (NYSE:ZTS)

Gofen & Glossberg LLC IL lowered its position in Zoetis Inc (NYSE:ZTS) by 1.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 262,843 shares of the company’s stock after selling 3,901 shares during the period. Zoetis comprises about 1.1% of Gofen & Glossberg LLC IL’s investment portfolio, making the stock its 28th biggest position. Gofen & Glossberg LLC IL’s holdings in Zoetis were worth $32,748,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. JJJ Advisors Inc. purchased a new position in Zoetis in the second quarter worth $25,000. Prestige Wealth Management Group LLC purchased a new position in Zoetis in the second quarter worth $27,000. Altshuler Shaham Ltd grew its position in Zoetis by 198.8% in the second quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock worth $29,000 after acquiring an additional 169 shares in the last quarter. Next Capital Management LLC grew its position in Zoetis by 156.5% in the second quarter. Next Capital Management LLC now owns 295 shares of the company’s stock worth $33,000 after acquiring an additional 180 shares in the last quarter. Finally, Destination Wealth Management grew its position in Zoetis by 217.9% in the second quarter. Destination Wealth Management now owns 337 shares of the company’s stock worth $38,000 after acquiring an additional 231 shares in the last quarter. 90.09% of the stock is currently owned by hedge funds and other institutional investors.

NYSE ZTS traded up $1.22 during trading on Thursday, hitting $127.65. 865,081 shares of the company’s stock traded hands, compared to its average volume of 2,007,441. The stock has a fifty day moving average of $125.13 and a two-hundred day moving average of $112.69. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. Zoetis Inc has a 12-month low of $78.90 and a 12-month high of $130.08. The firm has a market cap of $60.21 billion, a P/E ratio of 40.78, a PEG ratio of 3.12 and a beta of 0.87.



Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.08. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.51 billion. During the same period in the prior year, the business posted $0.77 earnings per share. The company’s revenue was up 9.3% on a year-over-year basis. As a group, analysts expect that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Tuesday, October 22nd will be given a dividend of $0.164 per share. The ex-dividend date is Monday, October 21st. This represents a $0.66 annualized dividend and a yield of 0.51%. Zoetis’s payout ratio is 21.09%.

Several research analysts recently issued reports on the stock. Argus set a $140.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Stifel Nicolaus set a $140.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, September 13th. Goldman Sachs Group assumed coverage on shares of Zoetis in a research report on Monday, September 9th. They issued a “conviction-buy” rating and a $145.00 target price for the company. Craig Hallum upped their target price on shares of Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Barclays upped their target price on shares of Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Zoetis currently has a consensus rating of “Buy” and a consensus price target of $123.19.

In other news, EVP Roxanne Lagano sold 4,463 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $125.99, for a total transaction of $562,293.37. Following the completion of the sale, the executive vice president now directly owns 33,190 shares in the company, valued at $4,181,608.10. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Clinton A. Jr. Lewis sold 6,123 shares of the stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $113.09, for a total transaction of $692,450.07. Following the sale, the insider now owns 46,812 shares of the company’s stock, valued at $5,293,969.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,332 shares of company stock valued at $4,163,091. Company insiders own 0.29% of the company’s stock.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: How much can an individual set aside as a catch-up contribution?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.